Study protocol of an open labeled randomized standard controlled clinical trial to evaluate the efficacy of Navayasa Lauha, Gomutra Haritaki and Dhanvantara Ghrita in management of diabetic dyslipidemia (Apthya Nimittaja Prameha)
Journal of Ayurveda and Integrated Medical Sciences · 12.08.2026 · 11 (7) · 191-196
DOI: 10.21760/jaims.11.7.28 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Journal of Ayurveda and Integrated Medical Sciences, online erschienen am 12.08.2026. Verfasst von Karan Surati und 1 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Diabetic dyslipidaemia, a key metabolic disorder associated with type 2 diabetes, is characterized by elevated triglycerides, reduced HDL, and increased small dense LDL, largely driven by insulin resistance and altered lipid metabolism. In Ayurvedic terms, it parallels Apthya Nimittaja Prameha, where Kapha and Meda vitiation, along with Ama formation, play a central role. Conventional lipid-lowering therapies often come with adverse effects, highlighting the need for safer alternatives. This study explores the therapeutic potential of Navayasa Lauha, Gomutra Haritaki, and Dhanvantara Ghrita, which collectively exhibit Lekhana, Amapachana, and Rasayana action. Aim and Objective: The Primary aim is to assess the effect of oral administration of Navayasa Lauha, Gomutra Haritaki followed by Dhanvantara Ghrita on lipid profile parameters. The Secondary aim is to compare the efficacy of the Ayurvedic intervention with the standard control drug in improving lipid profile (total cholesterol, VLDL, LDL, HDL, triglycerides), HS-CRP, serum C-peptide levels and Serum Apolipoprotein-B associated with diabetic dyslipidaemia.
Methods
The study is an open-label randomized standard controlled interventional trial, with a sample size of 100 including both in the trial and standard control group. Participants in the trial group will receive Gomutra Haritaki, Navayasa Lauha for 8-week period and Shamana Snehapana with Dhanvantara Ghrita will be introduced for 4 weeks. The participants in the control group will receive 2 placebo capsules alongside continuation of statins for 12 weeks. Outcome Measures: The primary outcomes of the study focus on the improvement of lipid profile, specifically marked by a reduction in serum triglyceride and serum LDL (low-density lipoprotein) levels, along with an increase in serum HDL (high-density lipoprotein) levels. The secondary outcomes include reduction in body weight and Body Mass Index (BMI), fasting blood sugar (FBS), postprandial blood sugar (PPBS), and Apolipoprotein B levels. Ethics: Ethical approval was taken from the Institutional Ethics Committee following which recruitment will be commenced in July 2025. Clinical Trial Registration: CTRI/2025/05/086703 (Registered on 09/05/2025)
Zitieren
APA
Surati, K., & Goyal, M. (2026). Study protocol of an open labeled randomized standard controlled clinical trial to evaluate the efficacy of Navayasa Lauha, Gomutra Haritaki and Dhanvantara Ghrita in management of diabetic dyslipidemia (Apthya Nimittaja Prameha). Journal of Ayurveda and Integrated Medical Sciences, 11(7), 191-196. https://doi.org/10.21760/jaims.11.7.28
Vancouver
Surati K, Goyal M. Study protocol of an open labeled randomized standard controlled clinical trial to evaluate the efficacy of Navayasa Lauha, Gomutra Haritaki and Dhanvantara Ghrita in management of diabetic dyslipidemia (Apthya Nimittaja Prameha). Journal of Ayurveda and Integrated Medical Sciences. 2026;11(7):191-196. doi:10.21760/jaims.11.7.28
BibTeX
@article{Surati2026,
author = {Surati, Karan and Goyal, Mandip},
title = {Study protocol of an open labeled randomized standard controlled clinical trial to evaluate the efficacy of Navayasa Lauha, Gomutra Haritaki and Dhanvantara Ghrita in management of diabetic dyslipidemia (Apthya Nimittaja Prameha)},
journal = {Journal of Ayurveda and Integrated Medical Sciences},
year = {2026},
volume = {11},
number = {7},
pages = {191--196},
doi = {10.21760/jaims.11.7.28}
}
EUVIMED